脓毒症心脏:分子机制与临床意义的当前认识
本文综述脓毒症心肌病的病理生理、诊断工具与治疗选择。患者通常表现为心室扩张、心室收缩力下降和/或左右心室功能障碍伴对容量输注反应降低,但缺乏一致的诊断标准。后负荷相关心脏性能联合斑点追踪超声心动图可能提高诊断准确性并指导治疗策略。由于没有特异性/病因性治疗,脓毒症休克现行指南构成脓毒症心肌病治疗的基石。作者强调需要进一步紧急研究以改善诊断并探索新的治疗靶点。
要点
- 脓毒症心肌病患者通常表现为心室扩张、心室收缩力下降和/或左右心室功能障碍伴对容量输注反应降低,但缺乏一致的诊断标准。
- 后负荷相关心脏性能联合斑点追踪超声心动图可能提供提高诊断准确性和指导治疗策略的方法。
- 由于没有特异性/病因性治疗,脓毒症休克现行指南是脓毒症心肌病治疗的基石。
- 脓毒症心肌病的发生是器官功能障碍的相关促成因素,也是脓毒症患者本已复杂的治疗管理中的重要因素。
- 作者强调需要进一步紧急研究以改善诊断并探索脓毒症心肌病的新治疗靶点。
适用人群与场景
- 脓毒症患者,存在脓毒症相关心血管衰竭(脓毒症心肌病)者。
诊断标准与关键阈值
- 脓毒症心肌病缺乏一致的诊断标准。
- 患者通常 exhibit 心室扩张、心室收缩力下降和/或左右心室功能障碍伴对容量输注反应降低。
处置流程与药物剂量
- 由于没有特异性/病因性治疗,脓毒症休克现行指南构成脓毒症心肌病治疗的基石。
- 后负荷相关心脏性能联合斑点追踪超声心动图可能用于指导治疗策略。
研究设计与关键结果
- 综述总结:脓毒症心肌病是脓毒症相关心血管衰竭的关键特征,尽管缺乏一致诊断标准,患者通常表现为心室扩张、心室收缩力下降和/或左右心室功能障碍伴对容量输注反应降低。
- 综述指出:脓毒症心肌病的存在是器官功能障碍的相关促成因素,也是脓毒症患者本已复杂的治疗管理中的重要因素。
- 综述提出:后负荷相关心脏性能联合斑点追踪超声心动图可能提供提高诊断准确性和指导治疗策略的方法。
- 综述指出:由于没有特异性/病因性治疗,脓毒症休克现行指南是脓毒症心肌病治疗的基石。
证据类型、等级与局限
- 证据类型:综述。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对脓毒症患者,脓毒症休克现行指南是脓毒症心肌病治疗的基石。
- 后负荷相关心脏性能联合斑点追踪超声心动图可能提高脓毒症心肌病的诊断准确性并指导治疗策略。
- 作者强调需要进一步紧急研究以改善诊断并探索脓毒症心肌病的新治疗靶点。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Septic cardiomyopathy is a key feature of sepsis-associated cardiovascular failure. Despite the lack of consistent diagnostic criteria, patients typically exhibit ventricular dilatation, reduced ventricular contractility, and/or both right and left ventricular dysfunction with a reduced response to volume infusion. Although there is solid evidence that the presence of septic cardiomyopathy is a relevant contributor to organ dysfunction and an important factor in the already complicated therapeutic management of patients with sepsis, there are still several questions to be asked: Which factors/mechanisms cause a cardiac dysfunction associated with sepsis? How do we diagnose septic cardiomyopathy? How do we treat septic cardiomyopathy? How does septic cardiomyopathy influence the long-term outcome of the patient? Each of these questions is interrelated, and the answers require a profound understanding of the underlying pathophysiology that involves a complex mix of systemic factors and molecular, metabolic, and structural changes of the cardiomyocyte. The afterload-related cardiac performance, together with speckle-tracking echocardiography, could provide methods to improve the diagnostic accuracy and guide therapeutic strategies in patients with septic cardiomyopathy. Because there are no specific/causal therapeutics for the treatment of septic cardiomyopathy, the current guidelines for the treatment of septic shock represent the cornerstone of septic cardiomyopathy therapy. This review provides an up-to-date overview of the current understanding of the pathophysiology, summarizes the evidence of currently available diagnostic tools and treatment options, and highlights the importance of further urgently needed studies aimed at improving diagnosis and investigating novel therapeutic targets for septic cardiomyopathy.
参考来源
- Martin L, Derwall M, Al Zoubi S, et al. The Septic Heart: Current Understanding of Molecular Mechanisms and Clinical Implications. Chest. 2018. PMID: 30171861. doi:10.1016/j.chest.2018.08.1037
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。